Zobrazeno 1 - 10
of 46
pro vyhledávání: '"R H, Blum"'
Publikováno v:
Journal of Clinical Oncology. 41:425-435
PURPOSE Interferon alfa-2b (IFN alpha-2b) exhibits antitumor activity in metastatic melanoma and on this basis has been evaluated as an adjuvant therapy following surgery for deep primary (T4) or regionally metastatic (N1) melanoma. METHODS A randomi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f40dc8aaae5afde85b40220c131fd5cd
https://doi.org/10.1200/jco.22.02264
https://doi.org/10.1200/jco.22.02264
Publikováno v:
The cancer journal from Scientific American. 6(1)
Six of the most active chemotherapy agents in small cell lung cancer were administered sequentially in a weekly fashion in an attempt to optimize the dose and the number of agents received over a 12-week period. The purpose of this study was to estim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8bc360eddc74e4e36ab3e36f3718b944
https://pubmed.ncbi.nlm.nih.gov/10696737
https://pubmed.ncbi.nlm.nih.gov/10696737
Autor:
W J, Tester, K M, Kim, R L, Krigel, P D, Bonomi, J H, Glick, R F, Asbury, J M, Kirkwood, R H, Blum, J H, Schiller
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 25(3)
Interleukin-2 (IL-2) and beta-interferon (beta-IFN) are biologic agents with antitumor activity observed in preclinical models. Some studies of patients with advanced non-small cell lung cancer treated with IL-2 report relatively long survival, despi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::932b33ff9d9c82b45584339b70e62d53
https://pubmed.ncbi.nlm.nih.gov/10512131
https://pubmed.ncbi.nlm.nih.gov/10512131
Autor:
J Wernz, Howard S. Hochster, M Meyers, J. Sanger, F. M. Muggia, E. Kramer, R. H. Blum, J. Speyer, A. Zeleniuch-Jacquotte, M. Rey, Michael D. Green
Publikováno v:
Cancer Treatment Reviews. 17:161-163
Doxorubicin is one of the most active drugs available for cancer chemotherapy. Its use is, however, often limited by the development of cumulative dose-related cardiomyopathy. The possibility ofinterfering with or preventing this toxicity in the clin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0c9b6f3864b953ee917334b26b9d338
https://doi.org/10.1016/0305-7372(90)90041-d
https://doi.org/10.1016/0305-7372(90)90041-d
Publikováno v:
Cancer. 82(2)
Patients with metastatic nonsmall cell lung carcinoma (NSCLC) usually have a poor prognosis. A chemotherapy regimen containing cisplatin is commonly used for symptom palliation. Echinomycin is a potent bifunctional intercalator of double-strand DNA;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e4956f6d1b7301413a986dc8ae296cd0
https://pubmed.ncbi.nlm.nih.gov/9445185
https://pubmed.ncbi.nlm.nih.gov/9445185
Autor:
R H, Blum
Publikováno v:
Oncology (Williston Park, N.Y.). 11(11)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bfc286e29125d12f373c1a282cfacae6
https://pubmed.ncbi.nlm.nih.gov/9394365
https://pubmed.ncbi.nlm.nih.gov/9394365
Autor:
H, Hochster, L, Liebes, J, Speyer, J, Sorich, B, Taubes, R, Oratz, J, Wernz, A, Chachoua, R H, Blum, A, Zeleniuch-Jacquotte
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 3(8)
Topoisomerase 1 (topo-1) inhibitors act on the target enzyme by forming "cleavable complex," a high molecular weight DNA protein adduct. The formation of such cleavable complexes results in depletion of the Mr 100,000 "free" topo-1 band detectable by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ede818240b8eb4a7048cf0e034f4ba14
https://pubmed.ncbi.nlm.nih.gov/9815806
https://pubmed.ncbi.nlm.nih.gov/9815806
Autor:
Peter Homel, M. Bookbinder, J. Nabatian, Stewart B. Fleishman, Victoria Rosenwald, E. Silen, R. H. Blum, S. Shah, B. Buddhdev
Publikováno v:
Journal of Clinical Oncology. 29:e19514-e19514
e19514 Background: A 2006 Institute of Medicine report, “From Cancer Patient to Cancer Survivor: Lost in Transition,” found gaps in communication, inattention to long- and short-term sequelae of tr...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c40530ec46802d0712d8363aa97a1ff1
https://doi.org/10.1200/jco.2011.29.15_suppl.e19514
https://doi.org/10.1200/jco.2011.29.15_suppl.e19514
Publikováno v:
Cancer chemotherapy and pharmacology. 31
On the basis of ifosfamide's demonstrated single-agent activity in adult soft-tissue sarcoma, the Eastern Cooperative Oncology Group (ECOG) tested whether ifosfamide would add to the efficacy of doxorubicin in a three-regimen, controlled phase III tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::be5be857477db384a6e5c66fd27cc49a
https://pubmed.ncbi.nlm.nih.gov/8453706
https://pubmed.ncbi.nlm.nih.gov/8453706
Autor:
Alain C. Mita, Jonathan Polikoff, Osvaldo Rudy Aren, Shirish M. Gadgeel, P. N. Mainwaring, Rebecca S. Heist, Lyudmila Bazhenova, R. H. Blum, Matthew A. Spear, J. Biswas
Publikováno v:
Journal of Clinical Oncology. 28:7592-7592
7592 Background: Plinabulin (NPI-2358) is a vascular disrupting agent (VDA) that acts on the cytoskeleton to destabilize tumor vascular endothelial cell cohesion with additional cytotoxic activity,...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a989ec9994b82df1647af19eabf9438
https://doi.org/10.1200/jco.2010.28.15_suppl.7592
https://doi.org/10.1200/jco.2010.28.15_suppl.7592